These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8872489)

  • 1. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
    Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
    Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis.
    Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Ohno Y; Masamoto T; Sakamoto H; Kato A; Washio Y; Hayashi M
    Ann Allergy Asthma Immunol; 1997 Sep; 79(3):213-20. PubMed ID: 9305226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours.
    Nano R; Capelli E; Argentina F; Facoetti A; Gerzeli G
    Cell Mol Biol (Noisy-le-grand); 2003 Jun; 49(4):525-8. PubMed ID: 12899444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of serum levels of interlukin-2 and its receptor, interlukin-6, sICAM-1, sVCAM-1 in patients with recurrent genital herpes].
    Zhang M; Zhang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):84-5. PubMed ID: 15600189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
    Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
    Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levels of anti-inflammatory cytokines interleukin-2, interleukin-8, and soluble interleukin-2 receptor in blood of patients with various forms of ischemic heart disease].
    Mazurov VI; Stvolov SV; Linetskaia NE; Baldueva IA
    Ter Arkh; 2001; 73(12):14-7. PubMed ID: 11858100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.
    Veelken H; Rosenthal FM; Schneller F; von Schilling C; Guettler IC; Herrmann F; Mertelsmann R; Lindemann A
    Biotechnol Ther; 1992; 3(1-2):1-14. PubMed ID: 1305889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
    Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
    Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
    Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
    Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.